美国系统性硬化症及SSc相关间质性肺病的疾病频率、患者特征、共病结局与免疫抑制治疗:一项队列研究
基于美国IBM MarketScan 2008-2017年理赔数据库,采用专家咨询制定的算法识别新诊断成人SSc及SSc-ILD患者。单条诊断码时SSc和SSc-ILD患病率分别为72.1/10万和19.0/10万,发病率分别为18.3/10万人年和4.3/10万人年;两条诊断码时患病率降至41.5/10万和13.3/10万,发病率降至8.8/10万人年和1.6/10万人年。SSc-ILD患者更年长、基线共病更多,基线接受免疫抑制治疗比例更高(12.7% vs 8.2%)。
要点
- 美国SSc及SSc-ILD均属罕见病,诊断算法灵敏度显著影响患病率与发病率估计。
- SSc-ILD患者较单纯SSc更年长、基线共病和诊断操作更多。
- MTX和MMF是最常用免疫抑制剂,SSc-ILD基线治疗率高于SSc。
核心结论
- SSc伴或不伴ILD在美国均属罕见病,新诊断SSc-ILD患者较新诊断SSc接受更多免疫抑制治疗且共病更多。
研究设计与样本
- 基于美国IBM MarketScan 2008-2017年理赔数据库的队列研究,采用专家咨询制定的算法识别新诊断成人SSc及SSc-ILD患者,并进行敏感性分析。
主要发现
- 单条诊断码时SSc和SSc-ILD患病率分别为72.1/10万和19.0/10万,发病率分别为18.3/10万人年和4.3/10万人年。
- 两条诊断码时SSc和SSc-ILD患病率分别为41.5/10万和13.3/10万,发病率分别为8.8/10万人年和1.6/10万人年。
- SSc-ILD患者更年长,基线共病和诊断操作更多。
- MTX和MMF是最常用免疫抑制剂,SSc-ILD基线治疗率12.7%,SSc为8.2%。
- SSc和SSc-ILD队列分别有42.5%和45.0%启动稳定免疫抑制方案,其中21.7%和19.4%出现升级。
关键数值与推荐
- SSc队列:新诊断成人(≥18岁)有≥1条SSc诊断理赔;SSc-ILD队列:额外有ILD理赔。
- 敏感性分析采用≥2条理赔或替代ILD诊断码。
- 随访期间皮肤疾病是两队列最常见的共病结局。
临床怎么用
- 临床解读SSc及SSc-ILD流行病学数据时需注意诊断算法定义对估计值的影响。
- 对新诊断SSc患者应评估ILD和共病,SSc-ILD患者可能需要更积极的免疫抑制治疗管理。
局限性
- 原文未报告基于理赔数据的诊断准确性验证及算法误分类程度。
- 原文未报告研究人群的地域代表性及未参保人群的外推性限制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To investigate prevalence estimates and incidence rates (IRs) for SSc and SSc-associated interstitial lung disease (SSc-ILD) cohorts and describe patient characteristics, immunosuppressive therapy (IST) and comorbid outcomes among incident SSc and SSc-ILD cohorts. METHODS: Data were obtained from the US IBM MarketScan (2008-2017) claims database using algorithms developed with expert consultation. For the SSc cohort, newly diagnosed patients (aged ≥18 years) had one or more diagnostic claim for SSc. For the SSc-ILD cohort, patients had an additional ILD claim. Sensitivity analyses using two or more claims or alternative ILD diagnostic codes were also conducted. RESULTS: When requiring one or more diagnostic claim, the prevalence of SSc and SSc-ILD per 100 000 persons was 72.1 and 19.0. The IR for SSc and SSc-ILD per 100 000 person-years was 18.3 and 4.3. Sensitivity analyses requiring two or more claims yielded much lower prevalence (SSc: 41.5; SSc-ILD: 13.3) and IR (SSc: 8.8; SSc-ILD: 1.6) estimates. Patients with SSc-ILD were older, with increased comorbidities and diagnostic procedures at baseline. MTX and MMF were the most common ISTs; 12.7% of the SSc-ILD cohort received therapy at baseline vs 8.2% for SSc. A total of 42.5% and 45.0% of the SSc and SSc-ILD cohorts, respectively, started a stable IST regimen and 21.7% and 19.4% of these had an escalation. Skin disorders were the most common comorbid outcome in both cohorts during follow-up. CONCLUSIONS: SSc, with or without associated ILD, is a rare disease in the US. Newly diagnosed patients with SSc-ILD had received more IST and had more comorbidities compared with newly diagnosed SSc.
引用
- Li Q, Wallace L, Patnaik P, et al. Disease frequency, patient characteristics, comorbidity outcomes and immunosuppressive therapy in systemic sclerosis and systemic sclerosis-associated interstitial lung disease: a US cohort study. Rheumatology (Oxford). 2021. PMID: 33155024. doi:10.1093/rheumatology/keaa547
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。